Form 8-K - Current report:
SEC Accession No. 0001104659-24-127439
Filing Date
2024-12-11
Accepted
2024-12-11 06:10:36
Documents
16
Period of Report
2024-12-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430444d2_8k.htm   iXBRL 8-K 28900
2 EXHIBIT 1.1 tm2430444d2_ex1-1.htm EX-1.1 257767
3 EXHIBIT 5.1 tm2430444d2_ex5-1.htm EX-5.1 9935
7 GRAPHIC tm2430444d2_ex5-1img001.jpg GRAPHIC 14858
  Complete submission text file 0001104659-24-127439.txt   558985

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA anvs-20241211.xsd EX-101.SCH 3021
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20241211_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20241211_pre.xml EX-101.PRE 22363
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2430444d2_8k_htm.xml XML 3781
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 241540053
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)